Prevention. Aspirin in primary prevention--good news and bad news

Nat Rev Cardiol. 2012 Feb 28;9(5):262-3. doi: 10.1038/nrcardio.2012.26.


The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.

MeSH terms

  • Aspirin / pharmacology*
  • Cardiovascular Diseases / prevention & control*
  • Cyclooxygenase Inhibitors / pharmacology*
  • Humans
  • Primary Prevention*
  • Risk Factors


  • Cyclooxygenase Inhibitors
  • Aspirin